Global Psychedelic Drugs Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF GLOBAL PSYCHEDELIC DRUGS MARKET 26
1.4 LIMITATIONS 28
1.5 MARKETS COVERED 29
2 MARKET SEGMENTATION 31
2.1 MARKETS COVERED 31
2.2 GEOGRAPHICAL SCOPE 32
2.3 YEARS CONSIDERED FOR THE STUDY 33
2.4 CURRENCY AND PRICING 33
2.5 DBMR TRIPOD DATA VALIDATION MODEL 34
2.6 MULTIVARIATE MODELLING 37
2.7 SOURCE LIFELINE CURVE 37
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38
2.9 DBMR MARKET POSITION GRID 39
2.10 MARKET APPLICATION COVERAGE GRID 40
2.11 VENDOR SHARE ANALYSIS 41
2.12 SECONDARY SOURCES 42
2.13 ASSUMPTIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 47
4.1 EPIDEMIOLOGY 49
4.2 PIPELINE ANALYSIS 51
5 REGULATORY FRAMEWORK: GLOBAL PSYCHEDELIC DRUGS MARKET 53
5.1 REGULATORY SCENARIO IN THE U.S. 53
5.2 REGULATORY SCENARIO IN THE U.K. 54
5.3 REGULATORY SCENARIO IN INDIA 55
5.4 REGULATORY SCENARIO IN UAE 55
5.5 REGULATORY SCENARIO IN AFRICA 56
5.6 REGULATORY SCENARIO IN BRAZIL 56

6 MARKET OVERVIEW 58
6.1 DRIVERS 60
6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION 60
6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS 62
6.1.3 RISING AWARENESS TOWARDS MENTAL HEALTH 67
6.1.4 ONGOING CLINICAL TRIALS 68
6.1.5 RISE IN PRODUCT APPROVALS 69
6.2 RESTRAINTS 69
6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS 69
6.2.2 HIGH COST OF PSYCHEDELIC DRUGS 72
6.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS 75
6.3 OPPORTUNITIES 75
6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS 75
6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY 77
6.3.3 UPCOMING REHABILITATION CENTERS 79
6.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS 79
6.4 CHALLENGES 79
6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS 79
6.4.2 RISE IN ILLEGAL ALTERNATIVES 80
6.4.3 AVAILABILITY OF OTHER TREATMENT OPTIONS 81
7 COVID-19 IMPACT ON GLOBAL PSYCHEDELIC DRUGS MARKET 82
7.1 IMPACT ON PRICE 82
7.2 IMPACT ON DEMAND 82
7.3 IMPACT ON SUPPLY CHAIN 83
7.4 STRATEGIC DECISIONS FOR MANUFACTURERS 83
7.5 CONCLUSION 84
8 GLOBAL PSYCHEDELIC DRUGS MARKET, BY TYPE 85
8.1 OVERVIEW 86
8.2 EMPATHOGENS 89
8.3 DISSOCIATIVES 89
8.4 OTHERS 90
9 GLOBAL PSYCHEDELIC DRUGS MARKET, BY SOURCE 92
9.1 OVERVIEW 93
9.2 SYNTHETIC 96
9.3 NATURAL 96

10 GLOBAL PSYCHEDELIC DRUGS MARKET, BY DRUGS 98
10.1 OVERVIEW 99
10.2 GAMMA-HYDROXYBUTYRIC ACID 102
10.3 KETAMINE 102
10.4 PSILOCYBIN 103
10.5 OTHERS 104
11 GLOBAL PSYCHEDELIC DRUGS MARKET, BY APPLICATION 106
11.1 OVERVIEW 107
11.2 NARCOLEPSY 110
11.3 TREATMENT RESISTANT DEPRESSION 110
11.4 MAJOR DEPRESSIVE DISORDER 111
11.5 OPIATE ADDICTION 112
11.6 POST-TRAUMATIC STRESS DISORDER 113
11.7 OTHERS 114
12 GLOBAL PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION 115
12.1 OVERVIEW 116
12.2 ORAL 119
12.3 INHALATION 119
12.4 INJECTABLE 120
13 GLOBAL PSYCHEDELIC DRUGS MARKET, BY END USER 122
13.1 OVERVIEW 123
13.2 HOSPITALS 126
13.3 SPECIALTY CLINICS 126
13.4 HOMECARE 127
13.5 OTHERS 128
14 GLOBAL PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL 129
14.1 OVERVIEW 130
14.2 HOSPITALS PHARMACY 133
14.3 RETAIL PHARMACY 133
14.4 ONLINE PHARMACY 134

15 GLOBAL PSYCHEDELIC DRUGS MARKET, BY REGION 136
15.1 OVERVIEW 137
15.2 NORTH AMERICA 143
15.2.1 U.S. 150
15.2.2 CANADA 152
15.2.3 MEXICO 154
15.3 EUROPE 156
15.3.1 GERMANY 165
15.3.2 U.K. 167
15.3.3 FRANCE 169
15.3.4 ITALY 171
15.3.5 SPAIN 173
15.3.6 RUSSIA 175
15.3.7 POLAND 177
15.3.8 SWITZERLAND 179
15.3.9 NETHERLANDS 181
15.3.10 HUNGARY 183
15.3.11 AUSTRIA 185
15.3.12 NORWAY 187
15.3.13 IRELAND 189
15.3.14 BELGIUM 191
15.3.15 LITHUANIA 193
15.3.16 REST OF EUROPE 195
15.4 ASIA-PACIFIC 196
15.4.1 INDIA 203
15.4.2 AUSTRALIA 205
15.4.3 SOUTH KOREA 207
15.4.4 SINGAPORE 209
15.4.5 MALAYSIA 211
15.5 MIDDLE EAST & AFRICA 213
15.5.1 SAUDI ARABIA 220
15.5.2 ISRAEL 222
15.5.3 EGYPT 224
15.5.4 U.A.E 226
15.5.5 SOUTH AFRICA 228
15.6 SOUTH AMERICA 230
15.6.1 BRAZIL 237
15.6.2 ARGENTINA 239
15.6.3 REST OF SOUTH AMERICA 241
16 GLOBAL PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE 242
16.1 COMPANY SHARE ANALYSIS: GLOBAL 242
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 243
16.3 COMPANY SHARE ANALYSIS: EUROPE 244
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 245
17 SWOT ANALYSIS 246
18 COMPANY PROFILE 247
18.1 JAZZ PHARMACEUTICALS, INC. 247
18.1.1 COMPANY SNAPSHOT 247
18.1.2 REVENUE ANALYSIS 247
18.1.3 COMPANY SHARE ANALYSI 248
18.1.4 PRODUCT PORTFOLIO 248
18.1.5 RECENT DEVELOPMENTS 249
18.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 250
18.2.1 COMPANY SNAPSHOT 250
18.2.2 REVENUE ANALYSIS 250
18.2.3 COMPANY SHARE ANALYSIS 251
18.2.4 PRODUCT PORTFOLIO 251
18.2.5 RECENT DEVELOPMENTS 251
18.3 PFIZER INC. 253
18.3.1 COMPANY SNAPSHOT 253
18.3.2 REVENUE ANALYSIS 253
18.3.3 COMPANY SHARE ANALYSIS 254
18.3.4 PRODUCT PORTFOLIO 254
18.3.5 RECENT DEVELOPMENTS 254
18.4 AVADEL 256
18.4.1 COMPANY SNAPSHOT 256
18.4.2 REVENUE ANALYSIS 256
18.4.3 PRODUCT PORTFOLIO 257
18.4.4 RECENT DEVELOPMENTS 257
18.5 CELON PHARMA S.A. 258
18.5.1 COMPANY SNAPSHOT 258
18.5.2 PIPELINE PRODUCT PORTFOLIO 258
18.5.3 RECENT DEVELOPMENTS 258
18.6 COMPASS 259
18.6.1 COMPANY SNAPSHOT 259
18.6.2 PIPELINE PRODUCT PORTFOLIO 259
18.6.3 RECENT DEVELOPMENTS 259
18.7 CYBIN CORP. 260
18.7.1 COMPANY SNAPSHOT 260
18.7.2 PIPELINE PRODUCT PORTFOLIO 260
18.7.3 RECENT DEVELOPMENT 260
18.8 DEMERX 261
18.8.1 COMPANY SNAPSHOT 261
18.8.2 PIPELINE PRODUCT PORTFOLIO 261
18.8.3 RECENT DEVELOPMENT 261
18.9 EMPATHBIO 262
18.9.1 COMPANY SNAPSHOT 262
18.9.2 PIPELINE PRODUCT PORTFOLIO 262
18.9.3 RECENT DEVELOPMENT 262
18.10 F. HOFFMANN-LA ROCHE LTD 263
18.10.1 COMPANY SNAPSHOT 263
18.10.2 REVENUE ANALYSIS 263
18.10.3 PRODUCT PORTFOLIO 264
18.10.4 RECENT DEVELOPMENT 264
18.11 GABA THERAPEUTICS, INC. 265
18.11.1 COMPANY SNAPSHOT 265
18.11.2 PIPELINE PRODUCT PORTFOLIO 265
18.11.3 RECENT DEVELOPMENT 265
18.12 HIKMA PHARMACEUTICALS PLC 266
18.12.1 COMPANY SNAPSHOT 266
18.12.2 REVENUE ANALYSIS 266
18.12.3 PRODUCT PORTFOLIO 267
18.12.4 RECENT DEVELOPMENTS 267
18.13 MIND MEDICINE INC. 268
18.13.1 COMPANY SNAPSHOT 268
18.13.2 PIPELINE PRODUCT PORTFOLIO 268
18.13.3 RECENT DEVELOPMENTS 268
18.14 NEURORX, INC. 269
18.14.1 COMPANY SNAPSHOT 269
18.14.2 PIPELINE PRODUCT PORTFOLIO 269
18.14.3 RECENT DEVELOPMENTS 270
18.15 PHARMATHER HOLDINGS LTD. 271
18.15.1 COMPANY SNAPSHOT 271
18.15.2 PIPELINE PRODUCT PORTFOLIO 271
18.15.3 RECENT DEVELOPMENTS 272

18.16 USONAINSTITUTE.ORG 273
18.16.1 INSTITUTE SNAPSHOT 273
18.16.2 PIPELINE PRODUCT PORTFOLIO 273
18.16.3 RECENT DEVELOPMENTS 273
18.17 VERRIAN 274
18.17.1 COMPANY SNAPSHOT 274
18.17.2 PRODUCT PORTFOLIO 274
18.17.3 RECENT DEVELOPMENT 274
19 QUESTIONNAIRE 275
20 RELATED REPORTS 279